[Pathophysiology and treatment of trigeminal autonomic cephalalgias].
Trigeminal autonomic cephalalgias (TACs) are a group of primary headache disorders, which are characterized by strictly unilateral pain, together with ipsilateral cranial autonomic symptoms. TACs include cluster headache (CH), paroxysmal hemicrania (PH) and short-lasting unilateral neuralgiform headache attacks with conjunctival injection and tearing (SUNCT syndrome). These diseases all have one thing in common: an activation of trigeminal nociceptive afferentia with a reflex-like activation of cranial autonomic efferentia via the facial nerve. TACs show differences not only in the length and frequency of attacks but also in the response to drug treatment. It is important to recognize and differentiate between these syndromes because they react very well, but very selectively to therapy.
Goadsby
P J
PJ
Headache Group, Department of Neurology, University of California, San Francisco, CA, USA. goadsbyp@neurology.ucsf.edu
Cohen
A S
AS
D000284:Administration, Oral; D000588:Amines / Q000627:therapeutic use; D000700:Analgesics / Q000627:therapeutic use; D000779:Anesthetics, Local / Q000008:administration & dosage / Q000627:therapeutic use; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use; D003027:Cluster Headache / Q000175:diagnosis / Q000188:drug therapy / Q000503:physiopathology / Q000517:prevention & control; D003509:Cyclohexanecarboxylic Acids / Q000627:therapeutic use; D003937:Diagnosis, Differential; D005260:Female; D005632:Fructose / Q000031:analogs & derivatives / Q000627:therapeutic use; D000077206:Gabapentin; D006801:Humans; D007213:Indomethacin / Q000627:therapeutic use; D000077213:Lamotrigine; D008012:Lidocaine / Q000008:administration & dosage / Q000627:therapeutic use; D008297:Male; D008784:Methysergide / Q000627:therapeutic use; D009619:Nociceptors / Q000502:physiology; D010102:Oxygen Inhalation Therapy; D051302:Paroxysmal Hemicrania / Q000175:diagnosis / Q000503:physiopathology / Q000517:prevention & control; D050798:SUNCT Syndrome / Q000175:diagnosis / Q000188:drug therapy / Q000503:physiopathology / Q000517:prevention & control; D012702:Serotonin Antagonists / Q000627:therapeutic use; D017366:Serotonin Receptor Agonists / Q000008:administration & dosage / Q000627:therapeutic use; D018170:Sumatriptan / Q000008:administration & dosage / Q000627:therapeutic use; D000077236:Topiramate; D014227:Triazines / Q000627:therapeutic use; D051303:Trigeminal Autonomic Cephalalgias / Q000175:diagnosis / Q000188:drug therapy / Q000503:physiopathology / Q000517:prevention & control; D014276:Trigeminal Nerve / Q000503:physiopathology; D014662:Vasoconstrictor Agents / Q000008:administration & dosage / Q000627:therapeutic use; D014665:Vasodilator Agents / Q000627:therapeutic use; D014700:Verapamil / Q000627:therapeutic use; D005680:gamma-Aminobutyric Acid / Q000627:therapeutic use
D000588:Amines; D000700:Analgesics; D000779:Anesthetics, Local; D000894:Anti-Inflammatory Agents, Non-Steroidal; D003509:Cyclohexanecarboxylic Acids; D012702:Serotonin Antagonists; D017366:Serotonin Receptor Agonists; D014227:Triazines; D014662:Vasoconstrictor Agents; D014665:Vasodilator Agents; D000077236:Topiramate; D005632:Fructose; D005680:gamma-Aminobutyric Acid; D000077206:Gabapentin; D018170:Sumatriptan; D008012:Lidocaine; D014700:Verapamil; D000077213:Lamotrigine; D007213:Indomethacin; D008784:Methysergide